1875 — TOT Biopharm International Co Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$1.65bn
- HK$1.65bn
- CNY780.63m
- 17
- 23
- 71
- 26
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -299 | -288 | -261 | -50 | -37.8 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 53.6 | 12.9 | 11.8 | 28.5 | 36.5 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -33 | -19.6 | 40 | 43.4 | 14.7 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -251 | -263 | -175 | 59.9 | 56.4 |
Capital Expenditures | -37.3 | -22.2 | -115 | -240 | -203 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -13.8 | 34.7 | 6.92 | -42.6 | 39.1 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -51.1 | 12.5 | -108 | -283 | -164 |
Financing Cash Flow Items | -16.8 | 0 | 5.62 | 402 | -16 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 583 | -61.7 | 212 | 481 | 38.2 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 282 | -314 | -72.7 | 265 | -66.2 |